DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
Trusted Resources: News & Events
Latest announcements and gatherings
Novo Nordisk inked a global licence deal with biotech company EpiDestiny for sickle cell disease (“SCD”) program EPI01.
Per the deal, EpiDestiny will receive more than $400 million in upfront, development and sales milestone payments and will also get royalties on net sales. EpiDestiny retains all rights to continue development of EPI01 in oncology. EpiDestiny and Novo Nordisk will jointly develop EPI01 for SCD and beta-thalassaemia.
EPI01 is a novel, orally available, disease-modifying therapy to increase foetal haemoglobin (HbF) and interrupt SCD pathophysiology. EpiDestiny recently completed a phase I study with EPI01 in SCD patients demonstrating increased HbF expression and safety after eight weeks of administration in a small patient cohort.
news & eventsGene therapy may help cure sickle cell disease, study saysA gene therapy that could provide a perm...
news & eventsThese patients had sickle-cell disease. Experimental therapies might have cured themScientists have long known what causes s...
education & researchOpioid utilization patterns in United States patients with sickle cell diseaseSickle cell disease (SCD) is the most co...
news & eventsSickle Cell Treatment ‘Life-Changing’ for Brockton BrothersEmmanuel “Manny” Johnson, 21, of Bro...
education & researchMaternal/Perinatal Outcome in Women With Sickle Cell Disease: A Comparison of Two Time PeriodsObjective: To compare pregnancy outcome...
news & eventsEarly clinical trial data show gene therapy reversing sickle cell anemiaAfter over a decade of preclin...
news & eventsCould Gene Therapy Cure Sickle Cell Anemia?Nearly 20 years ago, scientists stunned ...
send a message
Don’t forget to join the oneSCDvoice community!
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.